George Kumar, Senior Director at AstraZeneca, shared a post on LinkedIn:
”The need for molecular tumor boards
“Genomic sequencing promises targeted treatment for every patient with cancer; the reality is much tougher to deliver”
Excellent “World view” from Prof. Funda Meric- Bernstam: Chair of the Department of Investigational Cancer Therapeutics — the Phase I Program at MD Anderson Cancer Center, the Medical Director of the Institute for Personalized Cancer Therapy (IPCT), and The Nellie B. Connally Chair in Breast Cancer at MD Anderson Cancer Center.
Screenshot shared with permission of Dr. Funda Meric- Bernstam
Courtesy: Nature Medicine”
More posts featuring George Kumar.